Your browser doesn't support javascript.
Severe SARS-CoV-2 disease in the context of a NF-κB2 loss-of-function pathogenic variant.
Abraham, Roshini S; Marshall, Joanna M; Kuehn, Hye Sun; Rueda, Cesar M; Gibbs, Amber; Guider, Will; Stewart, Claire; Rosenzweig, Sergio D; Wang, Huanyu; Jean, Sophonie; Peeples, Mark; King, Tiffany; Hunt, W Garrett; Honegger, Jonathan R; Ramilo, Octavio; Mustillo, Peter J; Mejias, Asuncion; Ardura, Monica I; Shimamura, Masako.
  • Abraham RS; Department of Pathology and Laboratory Medicine, Nationwide Children's Hospital, Columbus, Ohio. Electronic address: Roshini.Abraham@nationwidechildrens.org.
  • Marshall JM; Department of Pathology and Laboratory Medicine, Nationwide Children's Hospital, Columbus, Ohio.
  • Kuehn HS; Department of Laboratory Medicine, National Institutes of Health, Bethesda, Md.
  • Rueda CM; Department of Pathology and Laboratory Medicine, Nationwide Children's Hospital, Columbus, Ohio.
  • Gibbs A; Department of Pathology and Laboratory Medicine, Nationwide Children's Hospital, Columbus, Ohio.
  • Guider W; Division of Critical Care Medicine, Nationwide Children's Hospital and The Ohio State University College of Medicine, Columbus, Ohio; Department of Pediatrics, Nationwide Children's Hospital and The Ohio State University College of Medicine, Columbus, Ohio.
  • Stewart C; Division of Critical Care Medicine, Nationwide Children's Hospital and The Ohio State University College of Medicine, Columbus, Ohio; Department of Pediatrics, Nationwide Children's Hospital and The Ohio State University College of Medicine, Columbus, Ohio.
  • Rosenzweig SD; Department of Laboratory Medicine, National Institutes of Health, Bethesda, Md.
  • Wang H; Department of Pathology and Laboratory Medicine, Nationwide Children's Hospital, Columbus, Ohio.
  • Jean S; Department of Pathology and Laboratory Medicine, Nationwide Children's Hospital, Columbus, Ohio.
  • Peeples M; Department of Pediatrics, Nationwide Children's Hospital and The Ohio State University College of Medicine, Columbus, Ohio; Center for Vaccines and Immunity, The Abigail Wexner Research Institute, Nationwide Children's Hospital, Columbus, Ohio.
  • King T; Department of Pediatrics, Nationwide Children's Hospital and The Ohio State University College of Medicine, Columbus, Ohio; Center for Vaccines and Immunity, The Abigail Wexner Research Institute, Nationwide Children's Hospital, Columbus, Ohio.
  • Hunt WG; Department of Pediatrics, Nationwide Children's Hospital and The Ohio State University College of Medicine, Columbus, Ohio; Division of Infectious Diseases, Nationwide Children's Hospital, Columbus, Ohio.
  • Honegger JR; Department of Pediatrics, Nationwide Children's Hospital and The Ohio State University College of Medicine, Columbus, Ohio; Center for Vaccines and Immunity, The Abigail Wexner Research Institute, Nationwide Children's Hospital, Columbus, Ohio; Division of Infectious Diseases, Nationwide Children's
  • Ramilo O; Department of Pediatrics, Nationwide Children's Hospital and The Ohio State University College of Medicine, Columbus, Ohio; Center for Vaccines and Immunity, The Abigail Wexner Research Institute, Nationwide Children's Hospital, Columbus, Ohio; Division of Infectious Diseases, Nationwide Children's
  • Mustillo PJ; Department of Pediatrics, Nationwide Children's Hospital and The Ohio State University College of Medicine, Columbus, Ohio; Division of Allergy and Immunology, Nationwide Children's Hospital, Columbus, Ohio.
  • Mejias A; Department of Pediatrics, Nationwide Children's Hospital and The Ohio State University College of Medicine, Columbus, Ohio; Center for Vaccines and Immunity, The Abigail Wexner Research Institute, Nationwide Children's Hospital, Columbus, Ohio; Division of Infectious Diseases, Nationwide Children's
  • Ardura MI; Department of Pediatrics, Nationwide Children's Hospital and The Ohio State University College of Medicine, Columbus, Ohio; Division of Infectious Diseases, Nationwide Children's Hospital, Columbus, Ohio.
  • Shimamura M; Department of Pediatrics, Nationwide Children's Hospital and The Ohio State University College of Medicine, Columbus, Ohio; Center for Vaccines and Immunity, The Abigail Wexner Research Institute, Nationwide Children's Hospital, Columbus, Ohio; Division of Infectious Diseases, Nationwide Children's
J Allergy Clin Immunol ; 147(2): 532-544.e1, 2021 Feb.
Article in English | MEDLINE | ID: covidwho-1124838
ABSTRACT

BACKGROUND:

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel coronavirus that emerged recently and has created a global pandemic. Symptomatic SARS-CoV-2 infection, termed coronavirus disease 2019 (COVID-19), has been associated with a host of symptoms affecting numerous organ systems, including the lungs, cardiovascular system, kidney, central nervous system, gastrointestinal tract, and skin, among others.

OBJECTIVE:

Although several risk factors have been identified as related to complications from and severity of COVID-19, much about the virus remains unknown. The host immune response appears to affect the outcome of disease. It is not surprising that patients with intrinsic or secondary immune compromise might be particularly susceptible to complications from SARS-CoV-2 infection. Pathogenic loss-of-function or gain-of-function heterozygous variants in nuclear factor-κB2 have been reported to be associated with either a combined immunodeficiency or common variable immunodeficiency phenotype.

METHODS:

We evaluated the functional consequence and immunologic phenotype of a novel NFKB2 loss of function variant in a 17-year-old male patient and describe the clinical management of SARS-CoV-2 infection in this context.

RESULTS:

This patient required a 2-week hospitalization for SARS-CoV-2 infection, including 7 days of mechanical ventilation. We used biologic therapies to avert potentially fatal acute respiratory distress syndrome and treat hyperinflammatory responses. The patient had an immunologic phenotype of B-cell dysregulation with decreased switched memory B cells. Despite the underlying immune dysfunction, he recovered from the infection with intense management.

CONCLUSIONS:

This clinical case exemplifies some of the practical challenges in management of patients with SARS-CoV-2 infection, especially in the context of underlying immune dysregulation.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: NF-kappa B p52 Subunit / SARS-CoV-2 / COVID-19 Type of study: Case report / Diagnostic study / Experimental Studies / Prognostic study Topics: Variants Limits: Adolescent / Humans / Male Language: English Journal: J Allergy Clin Immunol Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: NF-kappa B p52 Subunit / SARS-CoV-2 / COVID-19 Type of study: Case report / Diagnostic study / Experimental Studies / Prognostic study Topics: Variants Limits: Adolescent / Humans / Male Language: English Journal: J Allergy Clin Immunol Year: 2021 Document Type: Article